Order your FREE ticket

Online programme overview

Download programme pdf >>

Note: the organisation keeps the right to make changes to the programme at any time.

  • 14:00

    Programme part I

  • 15:05

  • 15:30

    Programme part II

    • Prevention of the onset of disorders by lifestyle changes - Why Small Changes Matter

      Hosted by PwC

      Lifestyle related diseases are an important and an increasing problem, causing enormous medical, economic and social problems. The scientific platform Lifestyle4health promotes solutions based on lifestyle medicine, whereas the commercial platform FoodFirst Network (“the Netflix for a more healthy and energetic life”) promotes consumer applications. The patient and consumer data angle will also be explored in this session, because proper data management is a key to success.

      Presentations by:
      Karin Verzijden, Attorney at law at Axon Lawyers
      Hanno Pijl, Professor Diabetology at LUMC and Lifestyle4Health
      Jan Dekker, Managing Director FoodFirst Network

    • Developments in diagnostic Covid-19 testing

      Hosted by Axon Lawyers

      Anja Garritsen is CEO of Innatoss Laboratories. With a background in pharmacy and pharmaceutical industry (she led the Department of Target Discovery and subsequently Immune Therapeutics at Organon/Schering Plough/MSD in Oss from 2005-2011), she founded Innatoss in 2012 and became an entrepeneur. Innatoss Laboratories is developing and performing diagnostics for infectious diseases, in particular Lyme Disease and Q fever. In the history of Innatoss, performing diagnostic tests for the public has always been combined with increasing knowledge on that disease. In the field of Q fever, Innatoss works with Mass General in Boston and Oxford University on a innovative Q fever vaccine. It helps the WHO to generate a reference serum for Q fever serological test. Innatoss uses it know-how, network and patient cohorts in Lyme Disease to evaluate novel diagnostics in that field for internal product development as well as for partners with interesting technologies. This unique business model has been extended to COVID-19 in Spring 2020. The last 6 months have been a roller coaster with ever changing guidelines, competition (rather than partnership) between the public and private sector, and exciting emerging tests and vaccines. Dr Garritsen will share her journey with you.

    • Keynote lecture

      Hanneke Schuitemaker, Professor in Virology and VP Viral Vaccine Discovery & Translational Medicine at Janssen Vaccines & Prevention will give insights in the development of the Covid-19 vaccine at Janssen Vaccines in Leiden. 

      What happened from the moment the genetic sequence of SARS-CoV-2, was published and triggered an intense global R&D activity to develop a vaccine against the disease? The scale of the humanitarian and economic impact of the COVID-19 pandemic is driving evaluation of next-generation vaccine technology platforms through novel paradigms to accelerate development, market approval and manufacturing . Which strategy is applied by Janssen Vaccines?

Order your FREE ticket

Stay up to date with the latest news!

Newsletter subscribe